• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Academia

Latest News

Targeting GPRC5D Holds Promise in Multiple Myeloma
Targeting GPRC5D Holds Promise in Multiple Myeloma

April 3rd 2025

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.

The authors explained that underrepresentation of certain groups and countries in MASH clinical trials can be addressed through better collaboration and novel methodologies. | Image credit: Jo Panuwat D - stock.adobe.com
MASH Clinical Trials Historically Underrepresent Certain Groups

March 24th 2025

In SCLC, transcription factors have also been found to play a key role in chemoresistance, and differences in expression of transcription factors have been tied to drug sensitivities. | Image credit: Rasi-stock.adobe.com
Examination of FOXP1 in SCLC Yields Potential Strategy Against Chemoresistance

March 20th 2025

In patients with MDS and AML, the researchers found impaired neutrophil subset distribution compared with healthy individuals. | Image credit: keetazalay - stock.adobe.com
Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML

March 14th 2025

Just 4 of the 20 cell and gene therapy trials in the study submitted the same trial evidence to both the FDA and EMA. | Image credit: Treecha - stock.adobe.com
Uniform Global Standards, Processes Could Accelerate CGT Approvals, Access

March 13th 2025

<1
...
7891011
© 2025 MJH Life Sciences
AJMC®
All rights reserved.